[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622225":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":31,"responsibleParty":49,"collaborators":18,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":18,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":34,"whyStopped":18,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Seoul National University Bundang Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"LT4 group","EXPERIMENTAL","Participants in this group will receive levothyroxine",[13],"Drug: levothyroxine",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Participants in this group will not receive levothyroxine",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"DRUG","levothyroxine","Intervention description: Participants assigned to the LT4 group will begin receiving levothyroxine the day before CABG. The initial dose is 25 μg once daily, or 12.5 μg for participants weighing less than 60 kg. The dose will then be adjusted based on thyroid function test results to achieve target TSH levels of 0.4-2.0 μIU\u002FmL.",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Min Joo Kim, Professor","CONTACT","+82-31-787-7855","chorong24@gmail.com",[32],{"facility":33,"status":34,"city":35,"state":18,"zip":36,"country":37,"countryCode":18,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Department of Internal Medicine, Seoul National University Bundang Hospital","RECRUITING","Seongnam-si","13620","South Korea",{"type":39,"coordinates":40},"Point",[41,42],127.13778,37.43861,{"lat":42,"lon":41},[45],{"name":46,"role":28,"phone":47,"phoneExt":18,"email":48},"Kang","+82-787-7029","hjk@snubh.org",{"type":50,"investigatorFullName":51,"investigatorTitle":52,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Min Joo Kim","Professor of Internal Medicine","100622225","thyroid-hormone-replacement-after-coronary-artery-bypass-grafting-for-patients-with-subclinical-hypothyroidism-100622225",false,"NCT07380854","Thyroid Hormone Replacement After Coronary Artery Bypass Grafting for Patients With Subclinical Hypothyroidism","RepleniSH","Eligibility Criteria\n\n* Adults aged 19 to 90 years.\n* Patients scheduled to undergo coronary artery bypass graft (CABG) surgery.\n* Subclinical hypothyroidism (SCH), defined as a normal free thyroxine (free T4) level and a thyroid-stimulating hormone (TSH) level greater than 4 μIU\u002FmL, based on testing performed within 31 days prior to surgery.\n\nExclusion Criteria:\n\n* Patients who underwent repeat or emergency CABG surgery\n* Use of LT4 within the previous 4 weeks\n* Use of antithyroid drug use (propylthiouracil, methimazole, or carbimazole) within the previous 3 months\n* Severe comorbid conditions with a life expectancy of less than 1 year (e.g. advanced malignancy)","ALL","19 Years","90 Years",{"count":64,"type":65},338,"ESTIMATED","INTERVENTIONAL",[68],"NA","The goal of this clinical trial is to find out whether levothyroxine reduces complications and improves the prognosis of patients with subclinical hypothyroidism (SCH) undergoing coronary artery bypass grafting (CABG).\n\nThe main questions this study aims to answer are:\n\n• Does levothyroxine reduce major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, and new arrhythmias, in SCH patients undergoing CABG? Researchers will compare patients who take levothyroxine with those who do not.\n\nParticipants will:\n\n* Be randomly assigned to either receive levothyroxine or not\n* Start the medication one day before surgery if assigned to the treatment group.\n* Have regular follow-up visits to check thyroid function and cardiovascular events for up to five years after surgery.",[71],"Subclinical Hypothyroidism",[73,74,75,22],"subclinical hypothyroidism","coronary artery bypass grafting","thyroid hormones","2026-01-24",{"date":78,"type":79},"2026-02-02","ACTUAL",{"date":81,"type":79},"2022-02-27",{"date":83,"type":65},"2037-02-26",{"name":5,"class":6},1]